APL designs, develops, moulds and assembles rigid packaging for medical devices and pharmaceutical applications.
The company has an ISO 13485-certified production facility equipped with 30 injection moulding machines, whose capacities range from 25t to 485t.
The acquisition is Comar’s first effort to expand internationally and is intended to strengthen its manufacturing capability in the medical device and pharmaceutical packaging segments.
The combined entity will have a network of 11 manufacturing facilities and more than 1,200 employees worldwide.
Comar CEO Mike Ruggieri said: “We are so excited to welcome the APL team to the Comar family.
“As part of our global vision, we believe it is critical to have a presence in Europe to better serve our medical and pharmaceutical customers many of whom have a global reach.
“APL has superb quality, best-in-class manufacturing, and a spectacular management team that can carry our strategic initiatives forward. We look forward to a successful partnership and continuing our growth journey together.”
APL managing director Al Lawless said: “We have proudly served our customers for the last five decades and cannot wait to provide more for them in the future as a part of Comar.
“From the beginning, we have trusted in Comar, their capabilities and, most importantly, their culture. They know how to partner with companies, mentor teams and empower them to drive growth.
“We truly believe Comar will bring the focus and resources necessary to elevate APL to the next level of performance.”
Private equity platform Morgan Stanley Capital Partners supported the transaction.
Based in New Jersey, Comar supplies custom medical devices and assemblies and speciality packaging solutions.
In December last year, the company acquired injection and blow-moulded product manufacturer Omega Packaging for an undisclosed sum.